Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Disufenton (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Oblato
- 28 Mar 2023 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 26 Sep 2021 Planned End Date changed from 1 Apr 2021 to 1 Oct 2022.
- 26 Sep 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2022.